Cardiome Pharma Corp (CRME) 9.40 $CRME Cardiome receives

New Post Public Reply Private Reply Replies (0) Message Board

Apr 26, 2015 at 2:17 PM

Cardiome Pharma Corp (CRME) 9.40 $CRME

Cardiome receives reimbursement status for BRINAVESS in Belgium
M2 - Fri Apr 10, 5:51AM CDT
Pharmaceutical company Cardiome Pharma (NASDAQ:CRME)(TSX:COM) reported on Thursday the receipt of approval of BRINAVESS for reimbursement by Belgium's national compulsory health care and benefits insurance authority, The National Institute for Health and Disability Insurance (Institut National d'Assurance Maladie Invalidite or INAMI).
CRME: 9.40 (-0.26), COM.TO: 11.38 (-0.31)

Cardiome Receives BRINAVESS Reimbursement Approval from Belgian Authorities
PR Newswire Europe - Thu Apr 09, 7:31AM CDT
VANCOUVER, British Columbia, April 9, 2015 /PRNewswire/ --
CRME: 9.40 (-0.26), COM.TO: 11.38 (-0.31)

13.6% Return Seen to Date on SmarTrend Cardiome Pharma Call (CRME)
Comtex SmarTrend(R) - Thu Mar 26, 9:41AM CDT
SmarTrend identified a Downtrend for Cardiome Pharma (NASDAQ:CRME) on February 4th, 2015 at $9.38. In approximately 2 months, Cardiome Pharma has returned 13.65% as of today's recent price of $8.10.
CRME: 9.40 (-0.26)

Cardiome Pharma's (CRME) CEO William Hunter on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Mar 12, 12:48PM CDT

CRME: 9.40 (-0.26)

Cardiome Pharma misses by $0.25, misses on revenue
Seeking Alpha - at Seeking Alpha - Thu Mar 12, 6:13AM CDT

CRME: 9.40 (-0.26)

Cardiome reports fourth quarter and full year 2014 financial results
CNW Group - Thu Mar 12, 6:00AM CDT
- Cardiome to conduct conference call and webcast today, March 12, at 8:00 a.m. Eastern (5:00 a.m. Pacific)
CRME: 9.40 (-0.26), COM.TO: 11.38 (-0.31)

Notable earnings before Thursday’s open
Seeking Alpha - at Seeking Alpha - Wed Mar 11, 4:30PM CDT

CRME: 9.40 (-0.26), JASO: 10.15 (-0.26), QIWI: 26.46 (-0.20), PGEM: 14.25 (-0.01), KIRK: 24.35 (+0.50), TLP: 35.92 (-0.44), CVGW: 51.00 (+0.42), GCO: 72.08 (+0.36), CSTM: 19.15 (+0.95), CMN: 48.03 (-0.10), HOV: 3.20 (unch), RICE: 22.11 (-0.46), PWE: 2.41 (-0.03), GLP: 41.41 (+0.90), BONT: 7.35 (+0.19), PLCE: 62.53 (-0.33), SNSS: 2.69 (+0.04), LEAF: 52.80 (+0.22), DG: 76.61 (+0.36), MTN: 104.05 (-1.28), SMRT: 12.31 (+0.12)

Nasdaq stocks posting largest percentage decreases
AP - Tue Mar 10, 5:08PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
HTBX: 6.89 (-0.71), CRME: 9.40 (-0.26), CMTL: 31.21 (+0.15), ANY: 4.08 (-0.19), AKRX: 55.24 (-0.68), MIND: 4.80 (-0.16), LMIA: 11.77 (-0.06), ANTH: 5.20 (+0.31), ANAT: 101.35 (+0.58), TITN: 14.39 (-0.08), COM.TO: 11.38 (-0.31), NNBR: 25.12 (-0.01), CLMT: 27.83 (+0.14), VNR: 16.85 (+0.22)

Coronary Artery Disease Therapeutics Pipeline Market H1 2015 Research Report Available at RnRMarketResearch.com
PRWeb - Thu Feb 05, 7:31AM CST
The report "Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H1 2015″ provides comprehensive information on the therapeutic development for Coronary Artery Disease (CAD) (Ischemic Heart Disease). Coronary artery disease (Ischemic Heart Disease) is the most common type of heart disease. Coronary artery disease is the tightening or blockage of the coronary arteries. A severe adequate blockage may cause a heart attack. Coronary artery disease (Ischemic Heart Disease) is the foremost cause of death in US, UK and globally. Most ischaemic heart disease is caused by atherosclerosis. However there are a number of risk factors.
CRME: 9.40 (-0.26), GILD: 103.69 (-1.52), PSTI: 2.82 (-0.05), MRK: 57.60 (+0.09), AZN: 71.79 (-1.34), EGRX: 59.30 (-1.62), BMY: 65.80 (-0.20), RGDO: 1.42 (+0.13)

Cardiome Pharma Has Returned 17.5% Since SmarTrend Recommendation (CRME)
Comtex SmarTrend(R) - Tue Feb 03, 9:34AM CST
SmarTrend identified an Uptrend for Cardiome Pharma (NASDAQ:CRME) on November 13th, 2014 at $8.56. In approximately 3 months, Cardiome Pharma has returned 17.52% as of today's recent price of $10.06.
CRME: 9.40 (-0.26)

Cardiome Pharma Shares Up 20.9% Since SmarTrend's Buy Recommendation (CRME)
Comtex SmarTrend(R) - Tue Jan 27, 9:10AM CST
SmarTrend identified an Uptrend for Cardiome Pharma (NASDAQ:CRME) on November 13th, 2014 at $8.56. In approximately 3 months, Cardiome Pharma has returned 20.91% as of today's recent price of $10.35.
CRME: 9.40 (-0.26)

Atrial Fibrillation Therapeutic Pipeline Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Fri Jan 23, 3:31PM CST
The report "Atrial Fibrillation - Pipeline Review, H2 2015" provides comprehensive information on the therapeutic development for atrial fibrillation. Atrial fibrillation is the most ordinary type of arrhythmia. Atrial fibrillation is an unbalanced heartbeat that increases the threat of stroke and heart disease. Generally, the risk of developing atrial fibrillation increases with age and with other risk factors such as diabetes, high blood pressure, and underlying heart disease. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. The complete report is available at http://www.rnrmarketresearch.com/atrial-fibri...eport.html .
CRME: 9.40 (-0.26), GILD: 103.69 (-1.52), AZN: 71.79 (-1.34), BMY: 65.80 (-0.20), RGDO: 1.42 (+0.13)

Uptrend Call Working As Cardiome Pharma Stock Rises 28.6% (CRME)
Comtex SmarTrend(R) - Tue Jan 20, 9:30AM CST
SmarTrend identified an Uptrend for Cardiome Pharma (NASDAQ:CRME) on November 13th, 2014 at $8.56. In approximately 2 months, Cardiome Pharma has returned 28.62% as of today's recent price of $11.01.
CRME: 9.40 (-0.26)

Nasdaq stocks posting largest volume increases
AP - Thu Jan 15, 5:08PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
CRME: 9.40 (-0.26), SMSI: 1.52 (+0.02), DNBF: 25.62 (+0.62), PODD: 30.72 (+0.11), FLML: 15.88 (+0.02), QADB: 21.00 (+0.21), QADA: 25.68 (-0.08), WBKC: 24.61 (-0.12), COM.TO: 11.38 (-0.31), CMSB: 13.24 (-0.01), DWCH: 7.76 (-0.34)

Cardiome Pharma (CRME) in Focus: Stock Rises 5.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jan 15, 7:44AM CST
Cardiome Pharma Corp. (CRME) was a big mover last session, as the company saw its shares rise a little over 5%
CRME: 9.40 (-0.26), PETX: 15.86 (-0.43)

Cardiome Pharma Shares Up 19.5% Since SmarTrend's Buy Recommendation (CRME)
Comtex SmarTrend(R) - Tue Jan 13, 1:08AM CST
SmarTrend identified an Uptrend for Cardiome Pharma (NASDAQ:CRME) on November 13th, 2014 at $8.56. In approximately 2 months, Cardiome Pharma has returned 19.51% as of today's recent price of $10.23.
CRME: 9.40 (-0.26)

China Biotech Week In Review: Otsuka Buys Rights To ARIAD's Leukemia Drug
ChinaBio Today - at Seeking Alpha - Sun Dec 28, 11:30AM CST
Deals and Financings Otsuka Pharma (TYO: 4768) of Japan snagged marketing rights to Iclusig, a leukemia drug developed by ARIAD Pharmaceuticals (NASDAQ: ARIA ), for Japan, China and eight other Asian countries (see story ). Otsuka will pay $77.5...
CRME: 9.40 (-0.26), ARIA: 9.71 (+0.10)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

BJ's Brews a New Dessert Innovation with Pizookie

Banana Bread Meets Nutella in BJ's Latest Pizookie Right off the bat, let's cut to the heart of this dessert innovation. BJ's Restaurant & Brewhouse, traded under NASDAQ:BJRI, has fired up its dessert menu with something new: the Nutella® Gone Bananas Pizookie®. This isn't just another sweet treat—it’s a bold move, and if you're wondering why, you're in good...

Palmetto Publishing's M&A Guide Aims to Boost Home Services

Palmetto's New Release: Mergers & Acquisitions Focus Man, Palmetto Publishing just dropped a bombshell for home services aficionados with their latest M&A guide. Now, if you’re like me, swimming in stocks and always looking for that next big exit play, this one’s tailor-made for you. Mergers and acquisitions might not sound as flashy as the tech darlings or...

Sweco: Europe’s Water Resilience Faces Tough Challenges

Tackling Europe's Water Resilience Ah, water infrastructure—it's that unglamorous pillar we often overlook until nature reminds us of its importance, sometimes with a swift, wet slap across the face. Sweco's recent report might not grab flashy headlines, but it's a good reminder for Europe that smarter investments in water resilience ain't just good advice; it's a damn...

Bitcoin Mortgages: APX Ushers in New Canadian Era

Bitcoin Meets Canadian Mortgages: A Game Changer? Here's a scenario you didn't see coming: Bitcoin, the digital darling of the new millennium, now backing Canadian mortgages. If that doesn't get your financial senses tingling, maybe you haven't been paying attention. APX Lending, a pioneer in digital-asset-backed lending, is kicking open the doors to a fresh financial...

JELD-WEN Kicks Off 2027 Senior Notes Exchange

By Caleb Price Updated Oct 28, 2026 Category News Views 164

A Fresh Play: Swapping Old for New With a fresh brew in hand and the latest company maneuvers on the table, JELD-WEN's move to exchange its 4.875% Senior Notes due 2027 for new secured notes maturing in 2031 comes into focus. This ain't just some routine shuffling of papers. They're calling up eligible folks holding onto those old notes, saying, 'Why stick with the old...

CashNetUSA Faces Class Action Over Exploitative Rates

High-Risk Lending Meets Military Protections Ever seen a seemingly legal scheme that just leaves a sour taste? That's the vibe with CashNetUSA right now. They've landed in the hot seat over allegedly sky-high interest rates served up to folks who put on a uniform. We're talking about a proposed nationwide class action lawsuit accusing the lender of giving active-duty...

Navigating Commercial Leases: Insights from Brandon McClain

Beyond the Monthly Rent: Real Lease Considerations When it comes to picking out a commercial space, folks, we ain't just talking square footage and what's scribbled under monthly rent. There's a whole roster of stuff businesses need to vet before getting ink on that dotted line. This ain't just about signing a lease—it's sizing up whether a property plays ball with your...

HiTHIUM Powers Up Australia's Energy Storage Future

Just imagine, folks, a slice of the energy world reshaping right under our feet in good ol' Australia. That's the buzz HiTHIUM sparked at All Energy Australia as they showcased their fancy ?Power 6.9MWh, 8-hour long-duration battery storage system (BESS). It wasn’t just about the tech superiority but the strategic planting of stakes in the local energy market....

Victory Gala Honors Heroes, Raises Over $500K

A Night Celebrating Service and Sacrifice You know, in times like these, it’s refreshing to see events that focus on giving back rather than taking everything to the bank. Victory Home Remodeling, along with its nonprofit arm, the Victory Foundation, recently hosted their second annual gala in Woodland Park, New Jersey to give some much-needed limelight to those who put...

New Era at Farah & Farah: Layla Farah Joins Firm

Expanding the Family Legacy In the bustling city of Jacksonville, a fresh breeze has swept the corridors of the longtime legal fortress, Farah & Farah. Layla Farah, fresh off her swearing-in ceremony, has entered the ranks. It's not every day you see a purely family-driven outfit pulling together generations in such a dramatic way. Three kiddos now walking the halls of...